Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE: BCG vs Gemcitabine + Docetaxel in BCG Naïve High Grade NMIBC
NCT05538663Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2023
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, docetaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by ECOG-ACRIN Cancer Research Group. Started Feb 2023; status: active, not recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05538663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538663.